3 Stocks Dragging The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 57 points (0.3%) at 16,611 as of Monday, Aug. 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,452 issues advancing vs. 535 declining with 124 unchanged.

The Health Care sector currently sits up 1.1% versus the S&P 500, which is up 0.6%. On the negative front, top decliners within the sector include Allergan ( AGN), down 2.2%, Illumina ( ILMN), down 2.1%, HCA Holdings ( HCA), down 1.0%, Aetna ( AET), down 0.9% and Mylan ( MYL), down 0.8%. Top gainers within the sector include Alnylam Pharmaceuticals ( ALNY), up 3.5%, ResMed ( RMD), up 2.3%, Incyte ( INCY), up 2.1%, Smith & Nephew ( SNN), up 2.1% and Pharmacyclics ( PCYC), up 1.9%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Dr Reddy Laboratories ( RDY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Dr Reddy Laboratories is down $0.81 (-1.8%) to $44.30 on light volume. Thus far, 63,799 shares of Dr Reddy Laboratories exchanged hands as compared to its average daily volume of 367,000 shares. The stock has ranged in price between $44.16-$44.44 after having opened the day at $44.28 as compared to the previous trading day's close of $45.11.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr Reddy Laboratories has a market cap of $7.6 billion and is part of the drugs industry. Shares are up 8.9% year-to-date as of the close of trading on Friday. Currently there is 1 analyst that rates Dr Reddy Laboratories a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Dr Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Dr Reddy Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: GLV, GLO, RDY